Zacks Small Cap Research on MSN25m
CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations.
CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, ...